Ph.D. Supervisor, Professor, and Deputy Chief Pharmacist. Head of the Clinical Pharmacy and Director of the Department of Pharmacy at the First Affiliated Hospital of the University of Science and Technology of China (USTC).
Education and Work Experience
- 2004-2007: Doctor of Medicine in Pharmacology, Anhui Medical University
- 2018: Clinical Pharmacy and Pharmaceutical Management, Johns Hopkins University School of Medicine, USA
- 2019: Clinical Pharmacy and Pharmaceutical Management, National Cancer Institute of Naples, Italy
- 1993-Present: Department of Pharmacy, the First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Academic Achievements and Impact
In recent years, Dr. Tang has presided over 27 projects (including 4 National Natural Science Foundation of China). She has published over 70 papers as the first or corresponding author, (including 30 SCI papers). She has authored and co-authored four books and contributed to four others. She was dedicated to teaching and research in clinical pharmacy and has supervised 66 doctoral and master's students and mentored 5 postdoctoral fellows. She has received one third prize for scientific and technological progress in Anhui Province, two provincial first prizes for teaching achievements and led 10 new projects of the hospital. She is a member of the National Health Commission's Precision Medicine Remote Consultation Expert Committee, a peer reviewer for the National Natural Science Foundation, an expert for the National Licensed Pharmacist Work, a member of the Evidence-Based Pharmacy Committee of the Chinese Pharmaceutical Association, an executive director of the Anhui Pharmaceutical Association, vice-chair of the Pharmacoeconomics Committee and the Therapeutic Drug Monitoring Research Committee of the Anhui Pharmacological Society, and vice-chair of the Pharmaceutical Affairs Management Professional Committee of the Anhui Hospital Association.
Ongoing Projects (Principal Investigator Only)
1. Project Name: LncRNA LOC102549726/EGF/FOXO Regulation of Podocyte Apoptosis in Diabetic Nephropathy and the Role of Berberine
- Source: National Natural Science Foundation of China
- Funding: 1.1 million RMB
- Duration: 2022-01 to 2025-12
2. Project Name: Design and Mechanistic Study of Anticancer Platinum(IV) Prodrugs,
- Source: Department of Education of Anhui Province
- Funding: 0.2 million RMB
- Duration: 2023-01 to 2025-12
Main Research Areas (Graduate Programs)
Biology:
1. Medical Molecular Biology
2. Cellular Immunity, Molecular Mechanisms, and Drug Therapy
Research Content
Dr. Tang's research team focuses on the inflammatory and immune mechanisms of diabetic nephropathy, targeting glomerular mesangial cells and podocytes. They study the changes of non-coding RNAs and related signaling pathways under disease conditions at the molecular level, as well as their impact on cell function and disease progression. The team also investigates the effects of traditional Chinese medicine, particularly berberine, on diabetic nephropathy to identify new therapeutic drugs and targets. In addition, Dr. Tang's research team also focuses on the toxic side effects and drug resistance associated with platinum-based anti-tumor drugs. They aim to design and synthesize novel platinum(IV) prodrugs to overcome the shortcomings of traditional platinum drugs. They analyze their metabolic distribution and elucidate the anti-tumor mechanisms of these platinum(IV) prodrugs at the molecular level, which provides guidance for the design of new anti-tumor drugs and the identification of new drug targets.
Representative Papers (Last Five Years) (* Corresponding Author)
1. Ni XY, Feng XJ, Wang ZH, Zhang Y, Little PJ, Cao Y, Xu SW, Tang LQ*, Weng JP, Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway. Acta Pharmacol Sin. 2024, 45(8):1604-1617.
2. Yang L#, Yuan SM #, Wang RR, Guo XY, Xie YS, Wei W*, Tang LQ*, Exploring the molecular mechanism of berberine for treating diabetic nephropathy based on network pharmacology. International Immunopharmacology 126 (2024) 111237.
3. Tang QL, Shi WT, Liu M, Tang LQ*, Ren W, Shi SL*, Mitochondrial protein MPV17 promotes β-cell apoptosis in diabetogenesis. Clin Sci, 2023, 137(15):1195-1208.
4. Shao YW#, Deng SJ#, Tang W#, Huang LZ, Xie YS, Yuan SM*, Tang LQ *, Molecular mechanism of GSDMD mediated glomerular endothelial cells pyroptosis: An implying in the progression of diabetic nephropathy. International Immunopharmacology 122 (2023) 110632.
5. Cheng FT, Geng YD, Liu YX, Nie X, Zhang XG, Chen ZL, Tang LQ*, Wang LH, You YZ*, Zhang L*, Co-delivery of a tumor microenvironment-responsive disulfiram prodrug and CuO2 nanoparticles for efficient cancer treatment. Nanoscale Adv. 2023;5(12):3336-3347.
6. Yuan SM, Zhu Y, Dai Y, Wang Y, Jin D, Liu MM, Tang LQ*, Arnesano F, Natile G*, Liu YZ*, 19F NMR Allows to Investigate the Fate of Platinum(IV) Prodrugs in Physiological Conditions. Angew. Chem. Int. Ed., 2022, 61, e202114250.
7.Zhou H#, Ni WJ#*, Meng XM *, Tang LQ*. MicroRNAs as regulators of immune and Inflammatory responses: potential therapeutic targets in diabetic nephropathy. Frontiers in cell and developmental biology, 2021; 8:618536
8. Deng MY, Su D, Xu SW, Little PJ, Feng XJ, Tang LQ*. ,Shen AZ*. Metformin and vascular diseases: a focused review on smooth muscle cell function. Frontiers in Pharmacology, 2020;11:635
9. Li C, Guan XM, Wang RY, Xie YS, Zhou H, Ni WJ*, Tang LQ*..Berberine mitigates high glucose-induced podocyte apoptosis by modulating autophagy via the mTOR/P70S6K/4EBP1 pathway. Life Sciences, 2020, 243:117277
10. Ni WJ, Zhou H, Ding HH, Tang LQ*. Berberine ameliorates renal impairment and inhibits podocyte dysfunction by targeting the phosphatidylinositol 3-kinase-protein kinase B pathway in diabetic rat. J Diabetes Investig. 2020,11(2):297-306
Contact Information
E-mail: tangliqin@ustc.edu.cn
Phone: 0551-62283008